Annie Liu

Conference Ann Surg Oncol · February 2025 BACKGROUND: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggest ... Full text Link to item Cite

Adjuvant Chemotherapy for Resected Intrahepatic Cholangiocarcinoma Confers No Survival Advantage.

Conference ANNALS OF SURGICAL ONCOLOGY · March 2023 Link to item Cite

Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage.

Conference JOURNAL OF CLINICAL ONCOLOGY · February 1, 2023 Link to item Cite

Perioperative and Oncologic Outcomes of Hepatic Artery Infusion Pump Therapy at an Expanding HAI Program

Conference ANNALS OF SURGICAL ONCOLOGY · May 2022 Link to item Cite

Patterns and Impact of Fractured Care on Outcomes in Stage II and III Gastric Cancer

Conference ANNALS OF SURGICAL ONCOLOGY · May 2022 Link to item Cite

Perioperative and oncologic outcomes of hepatic artery infusion pump therapy at an expanding HAI program.

Conference Journal of Clinical Oncology · February 1, 2022 120 Background: Hepatic artery infusion (HAI) is a liver directed therapy to treat unresectable or resected colorectal liver metastases (CRLM) and unresectable intrahepatic cholangiocarcinoma (ICC). Historically, HAI has only bee ... Full text Cite